scPharmaceuticals Announces Participation in Three Upcoming Investor Conferences
scPharmaceuticals Inc. (SCPH), a pharmaceutical company focused on cardiorenal healthcare innovations, has announced its participation in three upcoming investor conferences in May 2025. CEO John Tucker will present at:
- The Citizens Life Sciences Conference on May 7 at 9:30 a.m. ET
- H.C. Wainwright 3rd Annual BioConnect Investor Conference at NASDAQ on May 20 at 10:00 a.m. ET
- Craig-Hallum 22nd Annual Institutional Investor Conference on May 28 (investor meetings only)
Webcasts of the presentations will be available on the company's website under the Investor Relations section.
scPharmaceuticals Inc. (SCPH), un'azienda farmaceutica specializzata in innovazioni nel settore della salute cardiorenale, ha annunciato la sua partecipazione a tre conferenze per investitori previste per maggio 2025. Il CEO John Tucker interverrà in:
- The Citizens Life Sciences Conference il 7 maggio alle 9:30 ET
- H.C. Wainwright 3rd Annual BioConnect Investor Conference al NASDAQ il 20 maggio alle 10:00 ET
- Craig-Hallum 22nd Annual Institutional Investor Conference il 28 maggio (solo incontri con investitori)
Le registrazioni delle presentazioni saranno disponibili in webcast sul sito web dell'azienda, nella sezione Investor Relations.
scPharmaceuticals Inc. (SCPH), una compañía farmacéutica enfocada en innovaciones para la salud cardiorrenal, ha anunciado su participación en tres próximas conferencias para inversores en mayo de 2025. El CEO John Tucker presentará en:
- The Citizens Life Sciences Conference el 7 de mayo a las 9:30 a.m. ET
- H.C. Wainwright 3rd Annual BioConnect Investor Conference en NASDAQ el 20 de mayo a las 10:00 a.m. ET
- Craig-Hallum 22nd Annual Institutional Investor Conference el 28 de mayo (solo reuniones con inversores)
Las transmisiones en vivo de las presentaciones estarán disponibles en el sitio web de la compañía, en la sección de Relaciones con Inversores.
scPharmaceuticals Inc. (SCPH)는 심장 및 신장 건강 혁신에 중점을 둔 제약 회사로, 2025년 5월에 열리는 세 개의 투자자 컨퍼런스에 참여할 예정임을 발표했습니다. CEO John Tucker가 다음 행사에서 발표할 예정입니다:
- 5월 7일 오전 9시 30분 ET, The Citizens Life Sciences Conference
- 5월 20일 오전 10시 ET, NASDAQ에서 열리는 H.C. Wainwright 3rd Annual BioConnect Investor Conference
- 5월 28일, Craig-Hallum 22nd Annual Institutional Investor Conference (투자자 미팅 전용)
발표 웹캐스트는 회사 웹사이트의 투자자 관계 섹션에서 제공될 예정입니다.
scPharmaceuticals Inc. (SCPH), une société pharmaceutique spécialisée dans les innovations en santé cardiorénale, a annoncé sa participation à trois conférences pour investisseurs prévues en mai 2025. Le PDG John Tucker présentera lors de :
- The Citizens Life Sciences Conference le 7 mai à 9h30 ET
- H.C. Wainwright 3rd Annual BioConnect Investor Conference au NASDAQ le 20 mai à 10h00 ET
- Craig-Hallum 22nd Annual Institutional Investor Conference le 28 mai (réunions uniquement avec les investisseurs)
Les webdiffusions des présentations seront disponibles sur le site internet de la société, dans la section Relations Investisseurs.
scPharmaceuticals Inc. (SCPH), ein Pharmaunternehmen, das sich auf Innovationen im Bereich der kardiorenalen Gesundheitsversorgung spezialisiert hat, hat seine Teilnahme an drei bevorstehenden Investorenkonferenzen im Mai 2025 angekündigt. CEO John Tucker wird präsentieren bei:
- The Citizens Life Sciences Conference am 7. Mai um 9:30 Uhr ET
- H.C. Wainwright 3rd Annual BioConnect Investor Conference an der NASDAQ am 20. Mai um 10:00 Uhr ET
- Craig-Hallum 22nd Annual Institutional Investor Conference am 28. Mai (nur Investorenmeetings)
Webcasts der Präsentationen werden auf der Unternehmenswebsite im Bereich Investor Relations verfügbar sein.
- None.
- None.
BURLINGTON, Mass., May 01, 2025 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH) (the “Company”), a pharmaceutical company committed to revolutionizing cardiorenal healthcare through patient-centric innovations, today announced that John Tucker, President and Chief Executive Officer, will participate in the following upcoming investor conferences:
- The Citizens Life Sciences Conference: Presentation on Wednesday, May 7 at 9:30 a.m. ET.
- Craig-Hallum 22nd Annual Institutional Investor Conference: Wednesday, May 28, Investor Meetings Only
- H.C. Wainwright 3rd Annual BioConnect Investor Conference at NASDAQ: Presentation on May 20 at 10:00 a.m. ET.
A webcast of the presentations can be accessed here or under “News & Events” in the Investor Relations section of the Company’s website, www.scpharmaceuticals.com.
About scPharmaceuticals
At scPharmaceuticals, we are powered by passion, driven by patient care. Our Mission is focused on advancing cardiorenal care through innovative, integrated treatments that address unmet patient needs.
Our goal is to become the foremost advocate for patient-centric cardiorenal care, driving global health improvements through specialized, multidisciplinary approaches. scPharmaceuticals is expanding its reach, offering integrated therapies and products that address diverse healthcare needs and potentially improve the lives of our patients. scPharmaceuticals is headquartered in Burlington, MA. For more information, please visit www.scPharmaceuticals.com.
Katherine Miranda
scPharmaceuticals Inc., 781-301-6869
kmiranda@scpharma.com
Investors:
Nick Colangelo
Gilmartin Group, 339-225-1047
Nick@GilmartinIR.com
FAQ
When is SCPH presenting at the Citizens Life Sciences Conference in May 2025?
Which investor conferences is scPharmaceuticals (SCPH) attending in May 2025?
Who will represent scPharmaceuticals at these investor conferences?
Where can investors access the SCPH conference presentation webcasts?
